ViiV to Acquire Rights to HIV Drugs Created With Shionogi

GlaxoSmithKline Plc’s ViiV Healthcare Ltd. agreed to buy the rights to HIV treatments the unit has developed with Shionogi & Co., giving the Japanese drugmaker a 10 percent stake in ViiV as the companies prepare to seek approval of the most advanced medicine from the collaboration.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.